Search: onr:"swepub:oai:DiVA.org:kth-96444" >
Preclinical evaluat...
-
Altai, MohamedUppsala universitet,Enheten för biomedicinsk strålningsvetenskap,Vladimir Tolmachev
(author)
Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with In-111 using a maleimido derivative of NODAGA
- Article/chapterEnglish2012
Publisher, publication year, extent ...
-
Elsevier BV,2012
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:kth-96444
-
https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-96444URI
-
https://doi.org/10.1016/j.nucmedbio.2011.10.013DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-164424URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
QC 20120605
-
Introduction: Affibody molecules have demonstrated potential for radionuclide molecular imaging. The aim of this study was to synthesize and evaluate a maleimido derivative of the 1,4,7-triazacyclononane-l-glutaric acid-4,7-diacetic acid (NODAGA) for site-specific labeling of anti-HER2 Affibody molecule. Methods: The maleimidoethylmonoamide NODAGA (MMA-NODAGA) was synthesized and conjugated to Z(HER2:2395) Affibody molecule having a C-terminal cysteine. Labeling efficiency, binding specificity to and cell internalization by HER2-expressing cells of [In-111-MMA-NODAGA-Cys(61)]-Z(HER2:2395) were studied. Biodistribution of [In-111-MMA-NODAGA-Cys(61)]-Z(HER2:2395) and [In-111-MMA-DOTA-Cys(61)]-Z(HER2:2395) was compared in mice. Results: The affinity of [MMA-NODAGA-Cys(61)]-Z(HER2:2395) binding to HER2 was 67 pM. The In-1111-labeling yield was 99.6%+/- 0.5% after 30 min at 60 degrees C. [In-111-MMA-NODAGA-Cys(61)]-Z(HER2:2395) bound specifically to HER2-expressing cells in vitro and in vivo. Tumor uptake of [In-111-MMA-NODAGA-Cys(61)]-ZHER(2:2395) in mice bearing DU-145 xenografts (4.7%+/- 0.8% ID/g) was lower than uptake of [In-111-MMA-DOTA-Cys(61)]-Z(HER2:2395) (7.5%+/- 1.6% ID/g). However, tumor-to-organ ratios were higher for [In-111-MMA-NODAGA-Cys(61)]-Z(HER2:2395) due to higher clearance rate from normal tissues. Conclusions: MMA-NODAGA is a promising chelator for site-specific labeling of targeting proteins containing unpaired cysteine. Appreciable influence of chelators on targeting properties of Affibody molecules was demonstrated.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Perols, AnnaKTH,Molekylär Bioteknologi(Swepub:kth)u11lpgnl
(author)
-
Eriksson Karlström, AmelieKTH,Molekylär Bioteknologi(Swepub:kth)u10x6l4n
(author)
-
Sandström, MattiasUppsala universitet,Avdelningen för sjukhusfysik(Swepub:uu)masan637
(author)
-
Boschetti, Frederic
(author)
-
Orlova, AnnaUppsala universitet,Plattformen för preklinisk PET,Anna Orlova(Swepub:uu)annaorlo
(author)
-
Tolmachev, VladimirUppsala universitet,Enheten för biomedicinsk strålningsvetenskap,Vladimir Tolmachev(Swepub:uu)vladtolm
(author)
-
Uppsala universitetEnheten för biomedicinsk strålningsvetenskap
(creator_code:org_t)
Related titles
-
In:Nuclear Medicine and Biology: Elsevier BV39:4, s. 518-5290969-80511872-9614
Internet link
Find in a library
To the university's database